KIMBERLY SWARTZ: Open Payments
NPI 1497425169 · TROY, OH. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,515 in 113 payments from 14 companies in 2025. Trend: 2023 $112 · 2024 $1,628 · 2025 $2,515
Food & beverage: $2,511Education: $4
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 34 | $558 |
| Otsuka America Pharmaceutical, Inc. | 15 | $478 |
| Alkermes, Inc. | 12 | $327 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 16 | $325 |
| Vanda Pharmaceuticals Inc. | 13 | $247 |
| Xeris Pharmaceuticals, Inc. | 1 | $126 |
| Janssen Pharmaceuticals, Inc | 5 | $110 |
| Neurocrine BioSciences, Inc. | 4 | $85 |
| Collegium Pharmaceutical, Inc. | 3 | $57 |
| Teva Pharmaceuticals USA, Inc. | 3 | $54 |
Products named: VRAYLAR, REXULTI, CAPLYTA, LYBALVI, ARISTADA, RECORLEV, HETLIOZ, FANAPT.
Industry payments across OH — which companies pay providers there.
